IRVINE, Calif., April 7, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB:CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with Brazilian Biosciences National Laboratory (LNBio) to evaluate ChromaDex's natural product libraries.
ChromaDex and LNBio are establishing a collaboration to screen natural product libraries against certain molecular targets and phenotypic assays with the intent of identifying high value, possibly patentable natural products for specific therapeutic indications. Under the terms of the agreement, ChromaDex will be responsible for providing the natural product libraries for screening, as well as the natural product chemistry expertise to continue the development of any identified candidates into commercial opportunities. LNBio will screen the natural product libraries provided by ChromaDex, as well as continue performing assays in enzymes, cells and organisms related to the discovery of chemical entities that are the object of this collaboration.
"ChromaDex's expertise in developing natural product libraries, and natural products chemistry, as well as its success in commercializing novel, branded ingredients, makes ChromaDex the ideal partner for this type of high throughput screening collaboration," said Kleber Gomes Franchini, Director of LNBio. "If successful, this collaboration could lead to rapid commercialization of novel natural products for food, beverage, cosmetic or pharmaceutical applications."
"The ChromaDex catalog offers thousands of very unique phytochemical compounds primarily isolated from botanicals," said Frank Jaksch, Jr., founder and CEO of ChromaDex. "We are very excited to start this collaboration with LNBio, as this program will allow ChromaDex to extract value from the natural products library we have been developing over the past 15 years"
The Brazilian Biosciences National Laboratory (LNBio) is part of the Brazilian Center for Research in Energy and Materials (CNPEM), a private research and development institution (R&D) funded mainly by the Brazilian Ministry of Science, Technology, and Innovation (MCTI). LNBio is dedicated to research and innovation in biotechnology and drug discovery and development. The Laboratory activities are organized into four axes: Open Facilities; Innovation Core; Internal Research; Training and Education. This organizational strategy was designed to encourage the sharing of infrastructure and skills with the academic and industrial sectors. LNBio brings together competences, cutting edge equipment and a team of world-class researchers focused on conducting multidisciplinary studies in the areas of structural biology, proteomics, genomics, metabolomics, high-throughput screening (HTS) and high-content screening (HCS), development of genetically modified organisms (GMO), among others.
ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY, a caffeine-pTeroPure co-crystal; and NIAGEN, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Company Contact:
Laura Carney, Executive Assistant
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.